<p>RNS 编号：4191S 摩根大通证券有限公司 2026 年 2 月 10 日</p>
<p>表格 8.5 (EPT/RI)</p>
<p>由具有认可中介身份的豁免主要交易商进行的公共交易披露，服务于客户的能力</p>
<p>收购守则第 8.5 条（“守则”）</p>
<p>1. 关键信息</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>(a) 豁免主要交易商名称：</td>
<td>J.P. Morgan Securities Plc</td>
</tr>
<tr>
<td>(b) 与本表格相关的要约方/被要约方名称：<br/>每个要约方/被要约方使用单独的表格</td>
<td>Spire Healthcare Group plc</td>
</tr>
<tr>
<td>(c) 与豁免主要交易商相关的要约方名称：</td>
<td>Spire Healthcare Group PLC 的企业经纪人</td>
</tr>
<tr>
<td>(d) 交易日期：</td>
<td>2026 年 2 月 9 日</td>
</tr>
<tr>
<td>(e) 除上述 1(b) 中的公司外，豁免主要交易商是否对本要约的任何其他方进行披露？<br/>如果是现金要约或可能的现金要约，请说明 “无”</td>
<td>无</td>
</tr>
</tbody>
</table>
<p>2. 豁免主要交易商的交易</p>
<p>如果在 1(b) 中提到的要约方或被要约方的相关证券中有多个类别的交易，请为每个额外类别的相关证券复制表 2(a)、(b)、(c) 或 (d)（视情况而定）。</p>
<p>所有价格和其他货币金额的货币应予以说明。</p>
<p>(a) 购买和销售</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>相关证券类别</td>
<td>购买/销售</td>
<td>证券总数</td>
<td>每单位支付/收到的最高价格</td>
<td>每单位支付/收到的最低价格</td>
</tr>
<tr>
<td>1 便士普通股</td>
<td>购买</td>
<td>235,854</td>
<td>2.0550 英镑</td>
<td>1.9980 英镑</td>
</tr>
<tr>
<td>销售</td>
<td>191,032</td>
<td>2.0518 英镑</td>
<td>1.9960 英镑</td>
<td></td>
</tr>
</tbody>
</table>
<p>(b) 现金结算衍生品交易</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>相关证券类别</td>
<td>产品描述<br/>例如 CFD</td>
<td>交易性质<br/>例如 开仓/平仓多头/空头头寸，增加/减少多头/空头头寸</td>
<td>参考证券数量</td>
<td>每单位价格</td>
</tr>
<tr>
<td>1 便士普通股</td>
<td>股权互换</td>
<td>减少多头</td>
<td>21,178</td>
<td>2.0050 英镑</td>
</tr>
<tr>
<td></td>
<td></td>
<td>3,216</td>
<td>2.0051 英镑</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>10</td>
<td>2.0052 英镑</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>4,868</td>
<td>2.0054 英镑</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>278</td>
<td>2.0125 英镑</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>1</td>
<td>2.0127 英镑</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>6,830</td>
<td>2.0163 英镑</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>3,561</td>
<td>2.0200 英镑</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>20</td>
<td>2.0301 英镑</td>
<td></td>
</tr>
<tr>
<td></td>
<td>减少空头</td>
<td>315</td>
<td>2.0164 英镑</td>
<td></td>
</tr>
<tr>
<td></td>
<td>增加多头</td>
<td>3,637</td>
<td>2.0103 英镑</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>4,176</td>
<td>2.0105 英镑</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>8,117</td>
<td>2.0122 英镑</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>3,985</td>
<td>2.0133 英镑</td>
<td></td>
</tr>
<tr>
<td></td>
<td>开仓多头</td>
<td>1,751</td>
<td>2.0194 英镑</td>
<td></td>
</tr>
<tr>
<td></td>
<td>开仓空头</td>
<td>24,426</td>
<td>2.0050 英镑</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>1,751</td>
<td>2.0250 英镑</td>
<td></td>
</tr>
</tbody>
</table>
<p>(c) 股票结算衍生品交易（包括期权）</p>
<p>(i) 写入、出售、购买或变更</p>
<ul>
<li>相关证券类别</li>
</ul>
<ul>
<li>产品描述，例如看涨期权</li>
</ul>
<ul>
<li>写入、购买、出售、变更等。</li>
</ul>
<ul>
<li>与期权相关的证券数量</li>
</ul>
<ul>
<li>每单位行使价格</li>
</ul>
<ul>
<li>类型</li>
</ul>
<p>例如美式、欧式等。</p>
<ul>
<li>到期日</li>
</ul>
<ul>
<li>每单位支付/收到的期权费用</li>
</ul>
<p>(ii) 行使</p>
<ul>
<li>相关证券类别</li>
</ul>
<ul>
<li>产品描述</li>
</ul>
<p>例如看涨期权</p>
<ul>
<li>行使/已行使</li>
</ul>
<ul>
<li>证券数量</li>
</ul>
<ul>
<li>每单位行使价格</li>
</ul>
<p>(d) 其他交易（包括认购新证券）</p>
<ul>
<li>相关证券类别</li>
</ul>
<ul>
<li>交易性质</li>
</ul>
<p>例如认购、转换</p>
<ul>
<li>详情</li>
</ul>
<ul>
<li>每单位价格（如适用）</li>
</ul>
<p>3. 其他信息</p>
<p>(a) 赔偿和其他交易安排</p>
<ul>
<li>任何赔偿或期权安排的详情，或任何与相关证券有关的协议或理解，无论是正式还是非正式，可能会诱使豁免主要交易商进行或避免交易，涉及披露的豁免主要交易商与要约方或与要约方协同行动的任何人：</li>
</ul>
<p>不可撤销的承诺和意向书不应包括。如果没有此类协议、安排或理解，请说明 “无”</p>
<ul>
<li>无</li>
</ul>
<p>(b) 与期权或衍生品相关的协议、安排或理解</p>
<ul>
<li>任何与披露的豁免主要交易商和其他人之间的协议、安排或理解的详情，涉及：</li>
</ul>
<p>(i) 任何期权下相关证券的投票权；或</p>
<p>(ii) 任何衍生品所参考的相关证券的投票权或未来的收购或处置：</p>
<p>如果没有此类协议、安排或理解，请说明 “无”</p>
<ul>
<li>无</li>
</ul>
<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>披露日期：</td>
<td>2026 年 2 月 10 日</td>
</tr>
<tr>
<td>联系人姓名：</td>
<td>Hetvi Shah</td>
</tr>
<tr>
<td>电话号码：</td>
<td>44 2034 936359</td>
</tr>
</tbody>
</table>
<p>根据守则第 8 条的公共披露必须向监管信息服务进行。</p>
<p>小组的市场监测单位可就守则的交易披露要求提供咨询，电话：+44 (0) 20 7638 0129。</p>
<p>守则可在小组网站 www.thetakeoverpanel.org.uk 上查看。</p>
<p>此信息由 RNS 提供，伦敦证券交易所的新闻服务。RNS 获得金融行为监管局的批准，作为英国的主要信息提供者。有关使用和分发此信息的条款和条件可能适用。如需更多信息，请联系 rns@lseg.com 或访问 www.rns.com。</p>
<p>RNS 可能会使用您的 IP 地址以确认遵守条款和条件，分析您与此通信中包含的信息的互动，并将此分析以匿名方式与他人分享，作为我们商业服务的一部分。如需更多关于 RNS 和伦敦证券交易所如何使用您提供的个人数据的信息，请参见我们的隐私政策。结束 FERTMMLTMTABMRF</p>

JPM-D

SCHE

摩根大通

JPM-J

<p>摩根大通证券有限公司根据收购守则第 8.5 条披露了与 Spire Healthcare Group plc 相关的交易。2026 年 2 月 9 日，他们以每股价格在£1.9980 至£2.0550 之间购买了 235,854 股普通股，并以每股价格在£1.9960 至£2.0518 之间出售了 191,032 股。此外，他们还进行了多项现金结算的衍生品交易，包括减少和增加普通股的多头头寸。没有报告任何赔偿或期权安排。该披露由 Hetvi Shah 于 2026 年 2 月 10 日发布</p>

<p>RNS Number : 4191S JPMorgan Securities Plc 10 February 2026</p>
<div class="lb-trans"><p>RNS 编号：4191S 摩根大通证券有限公司 2026 年 2 月 10 日</p>
</div><p>FORM 8.5 (EPT/RI)</p>
<div class="lb-trans"><p>表格 8.5 (EPT/RI)</p>
</div><p>PUBLIC DEALING DISCLOSURE BY AN EXEMPT PRINCIPAL TRADER WITH RECOGNISED INTERMEDIARY STATUS DEALING IN A CLIENT-SERVING CAPACITY</p>
<div class="lb-trans"><p>由具有认可中介身份的豁免主要交易商进行的公共交易披露，服务于客户的能力</p>
</div><p>Rule 8.5 of the Takeover Code (the &#34;Code&#34;)</p>
<div class="lb-trans"><p>收购守则第 8.5 条（“守则”）</p>
</div><p>1. KEY INFORMATION</p>
<div class="lb-trans"><p>1. 关键信息</p>
</div><table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>(a) Name of exempt principal trader:</td>
<td>J.P. Morgan Securities Plc</td>
</tr>
<tr>
<td>(b) Name of offeror/offeree in relation to whose relevant securities this form relates:<br/>Use a separate form for each offeror/offeree</td>
<td>Spire Healthcare Group plc</td>
</tr>
<tr>
<td>(c) Name of the party to the offer with which exempt principal trader is connected:</td>
<td>Corporate Broker to Spire Healthcare Group PLC</td>
</tr>
<tr>
<td>(d) Date dealing undertaken:</td>
<td>09 February 2026</td>
</tr>
<tr>
<td>(e) In addition to the company in 1(b) above, is the exempt principal trader making disclosures in respect of any other party to this offer?<br/>If it is a cash offer or possible cash offer, state &#34;N/A&#34;</td>
<td>N/A</td>
</tr>
</tbody>
</table>
<div class="lb-trans"><table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>(a) 豁免主要交易商名称：</td>
<td>J.P. Morgan Securities Plc</td>
</tr>
<tr>
<td>(b) 与本表格相关的要约方/被要约方名称：<br/>每个要约方/被要约方使用单独的表格</td>
<td>Spire Healthcare Group plc</td>
</tr>
<tr>
<td>(c) 与豁免主要交易商相关的要约方名称：</td>
<td>Spire Healthcare Group PLC 的企业经纪人</td>
</tr>
<tr>
<td>(d) 交易日期：</td>
<td>2026 年 2 月 9 日</td>
</tr>
<tr>
<td>(e) 除上述 1(b) 中的公司外，豁免主要交易商是否对本要约的任何其他方进行披露？<br/>如果是现金要约或可能的现金要约，请说明 “无”</td>
<td>无</td>
</tr>
</tbody>
</table>
</div><p>2. DEALINGS BY THE EXEMPT PRINCIPAL TRADER</p>
<div class="lb-trans"><p>2. 豁免主要交易商的交易</p>
</div><p>Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(b), copy table 2(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.</p>
<div class="lb-trans"><p>如果在 1(b) 中提到的要约方或被要约方的相关证券中有多个类别的交易，请为每个额外类别的相关证券复制表 2(a)、(b)、(c) 或 (d)（视情况而定）。</p>
</div><p>The currency of all prices and other monetary amounts should be stated.</p>
<div class="lb-trans"><p>所有价格和其他货币金额的货币应予以说明。</p>
</div><p>(a) Purchases and sales</p>
<div class="lb-trans"><p>(a) 购买和销售</p>
</div><table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Class of relevant security</td>
<td>Purchases/ sales</td>
<td>Total number of securities</td>
<td>Highest price per unit paid/received</td>
<td>Lowest price per unit paid/received</td>
</tr>
<tr>
<td>1p ordinary</td>
<td>Purchase</td>
<td>235,854</td>
<td>2.0550 GBP</td>
<td>1.9980 GBP</td>
</tr>
<tr>
<td>Sale</td>
<td>191,032</td>
<td>2.0518 GBP</td>
<td>1.9960 GBP</td>
<td></td>
</tr>
</tbody>
</table>
<div class="lb-trans"><table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>相关证券类别</td>
<td>购买/销售</td>
<td>证券总数</td>
<td>每单位支付/收到的最高价格</td>
<td>每单位支付/收到的最低价格</td>
</tr>
<tr>
<td>1 便士普通股</td>
<td>购买</td>
<td>235,854</td>
<td>2.0550 英镑</td>
<td>1.9980 英镑</td>
</tr>
<tr>
<td>销售</td>
<td>191,032</td>
<td>2.0518 英镑</td>
<td>1.9960 英镑</td>
<td></td>
</tr>
</tbody>
</table>
</div><p>(b) Cash-settled derivative transactions</p>
<div class="lb-trans"><p>(b) 现金结算衍生品交易</p>
</div><table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Class of relevant security</td>
<td>Product description<br/>e.g. CFD</td>
<td>Nature of dealing<br/>e.g. opening/closing a long/short position, increasing/reducing a long/short position</td>
<td>Number of reference securities</td>
<td>Price per unit</td>
</tr>
<tr>
<td>1p ordinary</td>
<td>Equity Swap</td>
<td>Decrease Long</td>
<td>21,178</td>
<td>2.0050 GBP</td>
</tr>
<tr>
<td></td>
<td></td>
<td>3,216</td>
<td>2.0051 GBP</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>10</td>
<td>2.0052 GBP</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>4,868</td>
<td>2.0054 GBP</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>278</td>
<td>2.0125 GBP</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>1</td>
<td>2.0127 GBP</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>6,830</td>
<td>2.0163 GBP</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>3,561</td>
<td>2.0200 GBP</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>20</td>
<td>2.0301 GBP</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Decrease Short</td>
<td>315</td>
<td>2.0164 GBP</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Increase Long</td>
<td>3,637</td>
<td>2.0103 GBP</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>4,176</td>
<td>2.0105 GBP</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>8,117</td>
<td>2.0122 GBP</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>3,985</td>
<td>2.0133 GBP</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Opening a long position</td>
<td>1,751</td>
<td>2.0194 GBP</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Opening a short position</td>
<td>24,426</td>
<td>2.0050 GBP</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>1,751</td>
<td>2.0250 GBP</td>
<td></td>
</tr>
</tbody>
</table>
<div class="lb-trans"><table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>相关证券类别</td>
<td>产品描述<br/>例如 CFD</td>
<td>交易性质<br/>例如 开仓/平仓多头/空头头寸，增加/减少多头/空头头寸</td>
<td>参考证券数量</td>
<td>每单位价格</td>
</tr>
<tr>
<td>1 便士普通股</td>
<td>股权互换</td>
<td>减少多头</td>
<td>21,178</td>
<td>2.0050 英镑</td>
</tr>
<tr>
<td></td>
<td></td>
<td>3,216</td>
<td>2.0051 英镑</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>10</td>
<td>2.0052 英镑</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>4,868</td>
<td>2.0054 英镑</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>278</td>
<td>2.0125 英镑</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>1</td>
<td>2.0127 英镑</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>6,830</td>
<td>2.0163 英镑</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>3,561</td>
<td>2.0200 英镑</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>20</td>
<td>2.0301 英镑</td>
<td></td>
</tr>
<tr>
<td></td>
<td>减少空头</td>
<td>315</td>
<td>2.0164 英镑</td>
<td></td>
</tr>
<tr>
<td></td>
<td>增加多头</td>
<td>3,637</td>
<td>2.0103 英镑</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>4,176</td>
<td>2.0105 英镑</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>8,117</td>
<td>2.0122 英镑</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>3,985</td>
<td>2.0133 英镑</td>
<td></td>
</tr>
<tr>
<td></td>
<td>开仓多头</td>
<td>1,751</td>
<td>2.0194 英镑</td>
<td></td>
</tr>
<tr>
<td></td>
<td>开仓空头</td>
<td>24,426</td>
<td>2.0050 英镑</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>1,751</td>
<td>2.0250 英镑</td>
<td></td>
</tr>
</tbody>
</table>
</div><p>(c) Stock-settled derivative transactions (including options)</p>
<div class="lb-trans"><p>(c) 股票结算衍生品交易（包括期权）</p>
</div><p>(i) Writing, selling, purchasing or varying</p>
<div class="lb-trans"><p>(i) 写入、出售、购买或变更</p>
</div><ul>
<li>Class of relevant security</li>
</ul>
<div class="lb-trans"><ul>
<li>相关证券类别</li>
</ul>
</div><ul>
<li>Product description e.g. call option</li>
</ul>
<div class="lb-trans"><ul>
<li>产品描述，例如看涨期权</li>
</ul>
</div><ul>
<li>Writing, purchasing, selling, varying etc.</li>
</ul>
<div class="lb-trans"><ul>
<li>写入、购买、出售、变更等。</li>
</ul>
</div><ul>
<li>Number of securities to which option relates</li>
</ul>
<div class="lb-trans"><ul>
<li>与期权相关的证券数量</li>
</ul>
</div><ul>
<li>Exercise price per unit</li>
</ul>
<div class="lb-trans"><ul>
<li>每单位行使价格</li>
</ul>
</div><ul>
<li>Type</li>
</ul>
<div class="lb-trans"><ul>
<li>类型</li>
</ul>
</div><p>e.g. American, European etc.</p>
<div class="lb-trans"><p>例如美式、欧式等。</p>
</div><ul>
<li>Expiry date</li>
</ul>
<div class="lb-trans"><ul>
<li>到期日</li>
</ul>
</div><ul>
<li>Option money paid/ received per unit</li>
</ul>
<div class="lb-trans"><ul>
<li>每单位支付/收到的期权费用</li>
</ul>
</div><p>(ii) Exercise</p>
<div class="lb-trans"><p>(ii) 行使</p>
</div><ul>
<li>Class of relevant security</li>
</ul>
<div class="lb-trans"><ul>
<li>相关证券类别</li>
</ul>
</div><ul>
<li>Product description</li>
</ul>
<div class="lb-trans"><ul>
<li>产品描述</li>
</ul>
</div><p>e.g. call option</p>
<div class="lb-trans"><p>例如看涨期权</p>
</div><ul>
<li>Exercising/ exercised against</li>
</ul>
<div class="lb-trans"><ul>
<li>行使/已行使</li>
</ul>
</div><ul>
<li>Number of securities</li>
</ul>
<div class="lb-trans"><ul>
<li>证券数量</li>
</ul>
</div><ul>
<li>Exercise price per unit</li>
</ul>
<div class="lb-trans"><ul>
<li>每单位行使价格</li>
</ul>
</div><p>(d) Other dealings (including subscribing for new securities)</p>
<div class="lb-trans"><p>(d) 其他交易（包括认购新证券）</p>
</div><ul>
<li>Class of relevant security</li>
</ul>
<div class="lb-trans"><ul>
<li>相关证券类别</li>
</ul>
</div><ul>
<li>Nature of dealing</li>
</ul>
<div class="lb-trans"><ul>
<li>交易性质</li>
</ul>
</div><p>e.g. subscription, conversion</p>
<div class="lb-trans"><p>例如认购、转换</p>
</div><ul>
<li>Details</li>
</ul>
<div class="lb-trans"><ul>
<li>详情</li>
</ul>
</div><ul>
<li>Price per unit (if applicable)</li>
</ul>
<div class="lb-trans"><ul>
<li>每单位价格（如适用）</li>
</ul>
</div><p>3. OTHER INFORMATION</p>
<div class="lb-trans"><p>3. 其他信息</p>
</div><p>(a) Indemnity and other dealing arrangements</p>
<div class="lb-trans"><p>(a) 赔偿和其他交易安排</p>
</div><ul>
<li>Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the exempt principal trader making the disclosure and any party to the offer or any person acting in concert with a party to the offer:</li>
</ul>
<div class="lb-trans"><ul>
<li>任何赔偿或期权安排的详情，或任何与相关证券有关的协议或理解，无论是正式还是非正式，可能会诱使豁免主要交易商进行或避免交易，涉及披露的豁免主要交易商与要约方或与要约方协同行动的任何人：</li>
</ul>
</div><p>Irrevocable commitments and letters of intent should not be included. If there are no such agreements, arrangements or understandings, state &#34;none&#34;</p>
<div class="lb-trans"><p>不可撤销的承诺和意向书不应包括。如果没有此类协议、安排或理解，请说明 “无”</p>
</div><ul>
<li>None</li>
</ul>
<div class="lb-trans"><ul>
<li>无</li>
</ul>
</div><p>(b) Agreements, arrangements or understandings relating to options or derivatives</p>
<div class="lb-trans"><p>(b) 与期权或衍生品相关的协议、安排或理解</p>
</div><ul>
<li>Details of any agreement, arrangement or understanding, formal or informal, between the exempt principal trader making the disclosure and any other person relating to:</li>
</ul>
<div class="lb-trans"><ul>
<li>任何与披露的豁免主要交易商和其他人之间的协议、安排或理解的详情，涉及：</li>
</ul>
</div><p>(i) the voting rights of any relevant securities under any option; or</p>
<div class="lb-trans"><p>(i) 任何期权下相关证券的投票权；或</p>
</div><p>(ii) the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced:</p>
<div class="lb-trans"><p>(ii) 任何衍生品所参考的相关证券的投票权或未来的收购或处置：</p>
</div><p>If there are no such agreements, arrangements or understandings, state &#34;none&#34;</p>
<div class="lb-trans"><p>如果没有此类协议、安排或理解，请说明 “无”</p>
</div><ul>
<li>None</li>
</ul>
<div class="lb-trans"><ul>
<li>无</li>
</ul>
</div><table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Date of disclosure:</td>
<td>10 February 2026</td>
</tr>
<tr>
<td>Contact name:</td>
<td>Hetvi Shah</td>
</tr>
<tr>
<td>Telephone number:</td>
<td>44 2034 936359</td>
</tr>
</tbody>
</table>
<div class="lb-trans"><table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>披露日期：</td>
<td>2026 年 2 月 10 日</td>
</tr>
<tr>
<td>联系人姓名：</td>
<td>Hetvi Shah</td>
</tr>
<tr>
<td>电话号码：</td>
<td>44 2034 936359</td>
</tr>
</tbody>
</table>
</div><p>Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service.</p>
<div class="lb-trans"><p>根据守则第 8 条的公共披露必须向监管信息服务进行。</p>
</div><p>The Panel's Market Surveillance Unit is available for consultation in relation to the Code's dealing disclosure requirements on +44 (0) 20 7638 0129.</p>
<div class="lb-trans"><p>小组的市场监测单位可就守则的交易披露要求提供咨询，电话：+44 (0) 20 7638 0129。</p>
</div><p>The Code can be viewed on the Panel's website at www.thetakeoverpanel.org.uk.</p>
<div class="lb-trans"><p>守则可在小组网站 www.thetakeoverpanel.org.uk 上查看。</p>
</div><p>This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.</p>
<div class="lb-trans"><p>此信息由 RNS 提供，伦敦证券交易所的新闻服务。RNS 获得金融行为监管局的批准，作为英国的主要信息提供者。有关使用和分发此信息的条款和条件可能适用。如需更多信息，请联系 rns@lseg.com 或访问 www.rns.com。</p>
</div><p>RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy. END FERTMMLTMTABMRF</p>
<div class="lb-trans"><p>RNS 可能会使用您的 IP 地址以确认遵守条款和条件，分析您与此通信中包含的信息的互动，并将此分析以匿名方式与他人分享，作为我们商业服务的一部分。如需更多关于 RNS 和伦敦证券交易所如何使用您提供的个人数据的信息，请参见我们的隐私政策。结束 FERTMMLTMTABMRF</p>
</div>

REG - 摩根大通证券有限公司 Spire Healthcare 集团 - 表格 8.5（EPT/RI）- Spire Healthcare Group plc